Following the market opening Monday, the Dow traded down 1.10 percent to 24,310.81 while the NASDAQ declined 1.59 percent to 7,570.39. The S&P also fell, dropping 1.08 percent to 2,725.19.
Leading and Lagging Sectors;
Monday morning, the utilities shares surged 0.76 percent. Meanwhile, top gainers in the sector included Companhia Energética de Minas Gerais S.A. CIG 2.28% up 3 percent, and Alliant Energy Corporation LNT 2.82% up 2 percent.
In trading on Monday, information technology shares fell 1.8 percent.
Carnival Corporation CCL 8.99% reported better-than-expected earnings for its fiscal second quarter, but lowered its outlook for the full year.
The company said it earned 68 cents per share in the quarter on revenue of $4.4 billion versus expectations of 60 cents and $4.33 billion.
For 2018, Carnival now expects adjusted earnings of $4.15 to $4.25 per share, compared to earlier forecast of $4.20 to $4.40 per share.
Equities Trading UP;
Xerium Technologies, Inc. XRM 100% shares shot up 100 percent to $13.22 after Austria’s Andritz announced plans to buy the company for $833 million in a cash deal.
Shares of Valeritas Holdings, Inc. VLRX 31.07% got a boost, shooting up 29 percent to $1.83 after the company disclosed that ENABLE study data presented at the Annual ADA meeting reported that patients with Type 2 diabetes who switched to V-go had significant improvement in blood glucose and used less insulin.
Avid Bioservices, Inc. CDMO 7.93% shares were also up, gaining 10 percent to $3.8788. Avid Bioservices, has been added to the Russell 3000® Index and Russell 2000® Index.
Equities Trading DOWN;
Sophiris Bio, Inc. SPHS 41.6% shares dropped 40 percent to $2.24 after the company disclosed that it would cease secondary dosing of topsalysin following patient death on same day as 2nd administration.
Shares of Merrimack Pharmaceuticals, Inc. MACK 37.65% were down 34 percent to $6.05 after management discontinued the development of MM-141. The drug’s Phase 2 trial for MM-141 in front-line metastatic pancreatic cancer did not meet primary or secondary endpoints.
ERYTECH Pharma S.A. ERYP 27.86% was down, falling around 26 percent to $13.244 after the company announced plans to focus on development of eryaspase in solid tumors and ceases development in acute lymphoblastic leukemia.
In commodity news, oil traded up 0.89 percent to $69.19 while gold traded down 0.17 percent to $1,268.50.
Silver traded down 0.69 percent Monday to $16.345, while copper fell 0.44 to $3.0355.
European shares were lower today. The eurozone’s STOXX 600 dropped 1.32 percent, the Spanish Ibex Index fell 1.03 percent, while Italy’s FTSE MIB Index declined 1.30 percent. Meanwhile the German DAX dropped 1.66 percent, and the French CAC 40 slipped 0.89 percent while U.K. shares fell 1.60 percent.
The Chicago Fed National Activity Index declined to a reading of negative 0.15 for May, versus revised reading of positive 0.42 in April.
U.S. new home sales rose 6.7 percent to an annual rate of 689,000 in May.
The Dallas Fed manufacturing index for June is schedule for release at 10:30 a.m. ET.
The Treasury is set to auction 3-and 6-month bills at 11:30 a.m. ET.